Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$15.80
-$0.76(-7.27%)
At close: 4:00 PM EDT
$15.80
-$0.76(-7.27%)
Day’s Range― - ―
52-Week Range$1.50 - $16.33
Previous CloseN/A
Volume3.27M
Average Volume (3M)2.07M
Market Cap
$1.10B
Enterprise Value$988.94M
Total Cash (Recent Filing)$195.33M
Total Debt (Recent Filing)$111.97M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Oct 29, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding94,219,635
10 Day Avg. Volume1,632,874
30 Day Avg. Volume2,071,024
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.44
Forecast
1Y Price Target
$19.14Price Target Upside21.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$40.64M
Bulls Say, Bears Say
Bulls Say
Regulatory And Commercial ProgressAccelerated FDA approval gives Replimune a regulatory foothold in a difficult-to-treat melanoma setting and validates its oncolytic immunotherapy approach. Although confirmatory data remain required, the decision can support commercialization, physician adoption, and broader platform credibility.
Proprietary ImmunoVirotherapy PlatformA proprietary platform that combines tumor-selective viral replication with systemic immune activation can support multiple candidates and tumor types. This creates potential pipeline leverage, allowing clinical and regulatory know-how from lead programs to inform additional development opportunities.
Modest Balance-Sheet LeverageDebt remains modest relative to reported assets, limiting the immediate burden of interest and principal obligations. This provides more financial flexibility than a highly leveraged structure would, allowing capital allocation toward clinical development while the company advances its newly approved therapy.
Bears Say
Pre-Revenue Development ProfileThe absence of revenue means Replimune currently lacks a commercial base to absorb research, regulatory, and operating costs. Deepening losses also indicate that the approved product and pipeline must translate into sustained sales before the business can demonstrate operating leverage.
Severe Cash BurnSubstantial and still-worsening cash outflows require continued funding to maintain clinical programs and commercial activities. Persistent negative free cash flow can shorten financial runway, constrain strategic choices, and increase dependence on external capital before products generate meaningful cash.
Equity Erosion And Dilution RiskSharp equity erosion reflects the cumulative impact of sustained losses and reduces the shareholder capital cushion supporting operations. Expanded share authorization increases financing flexibility, but future equity issuance could dilute existing holders while the company remains cash-flow negative.
Replimune Group News
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $1.50 and its highest was $16.33 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $1.10B.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Aug 14, 2026. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.694 by -$0.026.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.78.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 94,219,635 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.694. Following the earnings report the stock price went down -1.448%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.14 (21.16% Upside)
$19.14 (21.16% Upside)
Blogger Sentiment
Neutral
REPL Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 644.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.45%
12-Months-Change
Fundamentals
Return on Equity
-159.32%
Trailing 12-Months
Asset Growth
-46.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Replimune Group Inc
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$19.14
▲(21.16% Upside)
Technical Analysis
CytomX Therapeutics
―
Immatics
―
Lyell Immunopharma
―
Candel Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
2.97% Insiders
15.52% Mutual Funds
0.20% Other Institutional Investors
67.10% Public Companies and
Individual Investors